Trials / Not Yet Recruiting
Not Yet RecruitingNCT07441486
A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Objective: To explore the curative effect and safty of Changchun Ruibin metronomic chemotherapy combined with endistat in the treatment of HR positive HER2 negative advanced breast carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Entinostat | Entinostat will be administered according to the study protocol. |
| DRUG | Oral Paclitaxel | Oral paclitaxel will be administered according to the study protocol. |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2026-04-10
- Completion
- 2026-08-30
- First posted
- 2026-03-02
- Last updated
- 2026-03-02
Source: ClinicalTrials.gov record NCT07441486. Inclusion in this directory is not an endorsement.